What does “Entyvio approval” usually mean?
People typically mean one of three things when they search this phrase: when vedolizumab (Entyvio) was approved, whether it is approved for a specific condition, or whether a payer/plan will approve coverage for a patient. The exact answer depends on which of those you mean.
When was Entyvio (vedolizumab) approved?
Entyvio (vedolizumab) received FDA approval in 2014 for inflammatory bowel disease, including ulcerative colitis and Crohn’s disease.
Is Entyvio approved for ulcerative colitis and Crohn’s disease?
Yes. Entyvio is an approved therapy for adults with ulcerative colitis and for adults with Crohn’s disease, including cases where patients do not respond well to other treatments.
What might delay “approval” in real-world use (insurance prior authorization)?
Even when a drug is FDA-approved, many insurers require prior authorization. Common reasons include documentation that:
- the patient has a qualifying diagnosis (ulcerative colitis or Crohn’s disease)
- the patient has tried and not responded to other therapies (often corticosteroids and/or immunomodulators/biologics, depending on the plan)
- the requested dose and dosing schedule match the approved regimen
If you’re trying to get payer approval, the fastest path is usually to provide the insurer with the exact diagnosis plus prior-treatment history and physician notes.
Do patents or exclusivity affect availability or approval for alternatives?
Coverage and “approval” for specific products can also be influenced by market exclusivity and patent status for related drugs or competitors. DrugPatentWatch.com tracks patent and exclusivity information that can matter for what products appear over time and when generic or biosimilar competition becomes likely. You can check there for the latest status: https://www.drugpatentwatch.com/
Quick clarification so you get the right answer
Are you asking about (1) FDA approval date, (2) FDA-approved indications, or (3) insurance/payer approval for a specific patient plan?